Bispecific Antibody Conjugation

Bispecific Antibody Conjugation

Bispecific antibodies have emerged as a promising class of therapeutic agents for the treatment of a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These antibodies are designed to target two different antigens simultaneously, allowing for more precise targeting and enhanced therapeutic efficacy. BOC Sciences' bispecific antibody conjugation services provide customers with comprehensive solutions for bispecific antibody development and production. Our expertise in bioconjugation, coupled with state-of-the-art facilities and cutting-edge technology, enables the production of high-quality bioconjugates with enhanced targeting capabilities and improved therapeutic efficacy. Whether you want to develop novel therapeutics or conduct bispecific antibody research, BOC Sciences can provide you with the custom solutions you need to achieve your goals.

Bispecific Antibodies (BsAbs)

Bispecific antibody (BsAb) is an engineered antibody that can bind to two specific epitopes or target proteins at the same time. It has the ability to bind two different epitopes at the same time and can play some special biological functions. For example, effector cells can be directly targeted to tumor cells to enhance their cytotoxicity, improve antibody selectivity and functionality, costimulate or inhibit receptors, avoid immune evasion mechanisms, and improve therapeutic effects. BsAb also reduces the cost of drug development and clinical trials compared with combined treatment with two monoclonal antibody drugs.

Bispecific antibody drug conjugates Fig. 1. Bispecific antibody drug conjugates (Acta Pharmaceutica Sinica B. 2024).

BsADCs have a novel dual-epitope/dual-target binding mode, which can not only expand the scope of drug treatment and improve tumor selectivity, but also significantly enhance the internalization effect of the drug. It is an emerging strategy for the development of a new generation of antibody-drug conjugate (ADC) drugs. Currently, ten BsADCs have entered clinical trials. BsADCs have the following advantages:

  • Simultaneously blocking two different targets or mediators that play a major role in disease pathogenesis.
  • Retargeting mediates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC).
  • Avoiding or delaying the development of drug resistance.
  • Inducing more potent antiproliferative effects.
  • Activating cytotoxic T cells and NK cells to induce tumor lysis.

Bispecific Antibody Conjugation Services

In order to design effective BsADC, target selection, antibody backbone, linker and payload drug all need to be uniquely summarized. For target selection, in addition to the criteria of traditional ADCs, the promotion effect of dual targets on internalization should be explored in detail. In addition, exploration of the dual-target specificity mechanism is necessary. The selection of antibody backbone and type and the generation strategy of bispecific antibodies are also of great significance to the design of BsADC. In addition to bispecific antibodies, the linker-payload of the drug should also be optimized as a whole to facilitate the characterization of new BsADC drugs, including characteristics such as linker type, side-killing effect, and DAR value.

One of the key advantages of BOC Sciences bispecific antibody conjugation services is our expertise in the development and production of complex bioconjugates. Our extensive experience in the conjugation of antibodies and other biomolecules allows us to provide our customers with customized bispecific antibody conjugation solutions. Our expert team works closely with clients to understand their specific requirements and develop customized bonding strategies to meet their needs.

Antibody Conjugation Services

BOC Sciences offers a range of conjugation options for bispecific antibodies, including site-specific conjugation, random conjugation, and conjugation with a variety of linkers and payloads. Our state-of-the-art facilities and cutting-edge technologies enable precise conjugation of bispecific antibodies, ensuring the production of high-quality bioconjugates with optimal stability and activity. Our conjugation strategies include:

Analysis and Characterization Services

BOC Sciences also offers a range of analytical services to support the characterization and validation of bispecific antibodies. These services include bioanalysis, stability testing, and quality control testing to ensure the production of high-quality bioconjugates that meet the highest quality and purity standards. Our experts utilize a variety of analytical techniques, including mass spectrometry, HPLC, and SDS-PAGE, to determine the efficiency and specificity of the conjugation process. Our team also utilizes a combination of techniques such as analytical ultracentrifugation, circular dichroism spectroscopy, and surface plasmon resonance to provide a comprehensive overview of bispecific antibodies.

Bispecific ADCs Development

BOC Sciences is a leading provider of bispecific ADC development services, offering comprehensive services including antibody modification, payload screening and linker synthesis. We also offer a range of other services to support the development of bispecific ADCs. This includes bioconjugation services to conjugate the antibody to the payload, as well as analytical services to characterize the properties of the bispecific ADC. We can also perform in vitro and in vivo studies to evaluate the pharmacokinetics, pharmacodynamics and safety of bispecific ADCs.

  • Antibody modification is a critical step in the development of bispecific ADCs. BOC Sciences offers a range of antibody engineering services to modify antibodies for use in ADCs. This includes the generation of bispecific antibodies that can target two different antigens on cancer cells, and the conjugation of antibodies with cytotoxic payloads.
  • BOC Sciences also offers comprehensive payload screening services to identify the most potent cytotoxic payloads for bispecific ADCs, including screening small molecule drug libraries to identify candidates with high potency and selectivity against cancer cells.
  • We also offer a range of linker synthesis services for the design and synthesis of linkers that can efficiently release cytotoxic payloads within cancer cells. BOC Sciences has expertise in linker chemistry to design linkers with optimal stability, cleavage kinetics and selectivity.

Why Choose BOC Sciences?

  • Expertise and Experience: BOC Sciences has a team of highly skilled scientists with extensive experience in antibody conjugation technology. They are able to provide expert advice and guidance on the best strategies for conjugating antibodies to various molecules such as small molecules, enzymes, fluorophores or nanoparticles.
  • One-stop customization: BOC Sciences provides a wide range of customized options for antibody coupling services, enabling researchers to customize their experiments to meet their specific needs, including the ability to select from a variety of conjugation methods, linkers, and detection systems.
  • High-quality reagents: BOC Sciences uses high-quality reagents and materials in its antibody conjugation services, ensuring reliable and reproducible results. This helps minimize experimental variability and improve the accuracy of research results.
  • Fast turnaround time: BOC Sciences is able to offer fast turnaround time for its antibody conjugation services, allowing researchers to receive their conjugated antibodies quickly and efficiently. This helps accelerate the pace of R&D projects.
  • Competitive pricing: BOC Sciences offers competitive pricing for its antibody conjugation services, making it an affordable option for researchers on a tight budget. This allows researchers to obtain high-quality conjugated antibodies without spending too much money.

Case Study

BOC Sciences' bispecific antibody conjugation services are a game-changer for a biotech company working to develop novel cancer therapies. The company has been working to find a reliable and efficient way to combine two different antibodies to create a bispecific antibody that can target multiple cancer cells simultaneously. After learning about BOC Sciences' expertise in antibody conjugation, the company decided to give our services a try. BOC Sciences' team of scientists worked closely with the biotech company to understand their specific needs and goals for the bispecific antibody.

The concept and design considerations of BsADCsFig. 2. The concept and design considerations of BsADCs (Acta Pharmaceutica Sinica B. 2024).

Leveraging its state-of-the-art technology and expertise in antibody conjugation, BOC Sciences successfully conjugated two antibodies together to create a highly potent bispecific antibody that has shown promise in preclinical studies the result of. The company is very excited about the results and is rapidly advancing further development and testing of its cancer therapy.


1. What do bispecific antibodies do?

Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time. This allows them to target two different molecules or cells simultaneously, thereby enhancing the therapeutic effect. Bispecific antibodies are being developed for a variety of applications, including cancer treatment, autoimmune diseases, and infectious diseases. They can redirect immune cells to attack specific targets, block two different signaling pathways, or deliver drugs to specific locations in the body.

2. What is the difference between monoclonal and bispecific antibody?

Monoclonal antibodies are antibodies produced by identical immune cells that are clones of a unique parent cell. They are specific for a single antigen and bind to a single target on a cell or molecule. Bispecific antibodies are antibodies designed to bind to two different antigens simultaneously. This allows them to target two different molecules or cells simultaneously, which can be used to direct immune cells to attack specific targets or block two different pathways simultaneously.


  1. Gu, Y. et al. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharmaceutica Sinica B. 2024.
* Only for research. Not suitable for any diagnostic or therapeutic use.
Send Inquiry
Verification code
Inquiry Basket